22nd Century Group (XXII) Acquires GVB Biopharma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
GVB Biopharma Acquisition "Adds Scale, Scope and Diversification" - Dawson James Bullish on 22nd Century Group (XXII) with $8.50 Price Target
May 16, 2022 8:14 AM EDTDawson James analyst James McILree reiterated a Buy rating and $8.50 price target on 22nd Century Group (NASDAQ: XXII), following the company's announcement it had acquired GVB Biopharma.
The analyst comments: "22nd Century announced the acquisition of GVB Biopharma, one of the largest producers of... More
